BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Damilakis E, Mavroudis D, Sfakianaki M, Souglakos J. Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival? Cancers (Basel) 2020;12:E889. [PMID: 32268531 DOI: 10.3390/cancers12040889] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Liu J, Wu C, Peng J, Wei Y, Cui S. Preoperative Prediction of Microsatellite Instability in Rectal Cancer Using Five Machine Learning Algorithms Based on Multiparametric MRI Radiomics. Diagnostics (Basel) 2023;13. [PMID: 36673079 DOI: 10.3390/diagnostics13020269] [Reference Citation Analysis]
2 Sfakianaki M, Tzardi M, Tsantaki K, Koutoulaki C, Messaritakis I, Datseri G, Moustou E, Mavroudis D, Souglakos J. Evaluation of Microsatellite Instability Molecular Analysis versus Immuno-Histochemical Interpretation in Malignant Neoplasms with Different Localizations. Cancers (Basel) 2023;15. [PMID: 36672302 DOI: 10.3390/cancers15020353] [Reference Citation Analysis]
3 Osterlund E, Glimelius B. Temporal development in survival, and gender and regional differences in the Swedish population of patients with synchronous and metachronous metastatic colorectal cancer. Acta Oncol 2022;:1-11. [PMID: 36152023 DOI: 10.1080/0284186X.2022.2126327] [Reference Citation Analysis]
4 Wozniakova M, Skarda J, Raska M. The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis. Pathol Oncol Res 2022;28:1610502. [DOI: 10.3389/pore.2022.1610502] [Reference Citation Analysis]
5 Huang L, Zhao H, Shan M, Chen H, Xu B, He Y, Zhao Y, Liu Z, Chen J, Xu Q. Oncolytic adenovirus H101 ameliorate the efficacy of anti-PD-1 monotherapy in colorectal cancer. Cancer Med 2022;11:4575-87. [PMID: 35762456 DOI: 10.1002/cam4.4845] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhou H, Wang Y, Lin Y, Cai W, Li X, He X. Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study. Front Oncol 2021;11:774445. [PMID: 34900725 DOI: 10.3389/fonc.2021.774445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Du F, Liu Y. Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer. J Clin Lab Anal 2021;:e24141. [PMID: 34817097 DOI: 10.1002/jcla.24141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Sain A, Sahu S, Naskar D. Potential of olive oil and its phenolic compounds as therapeutic intervention against colorectal cancer: a comprehensive review. Br J Nutr 2021;:1-17. [PMID: 34338174 DOI: 10.1017/S0007114521002919] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Zhuang Z, Liu Z, Li J, Wang X, Xie P, Xiong F, Hu J, Meng X, Huang M, Deng Y, Lan P, Yu H, Luo Y. Radiomic signature of the FOWARC trial predicts pathological response to neoadjuvant treatment in rectal cancer. J Transl Med 2021;19:256. [PMID: 34112180 DOI: 10.1186/s12967-021-02919-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Silveira MJ, Castro F, Oliveira MJ, Sarmento B. Immunomodulatory nanomedicine for colorectal cancer treatment: a landscape to be explored? Biomater Sci 2021;9:3228-43. [PMID: 33949441 DOI: 10.1039/d1bm00137j] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Cui G. The Mechanisms Leading to Distinct Responses to PD-1/PD-L1 Blockades in Colorectal Cancers With Different MSI Statuses. Front Oncol 2021;11:573547. [PMID: 33763344 DOI: 10.3389/fonc.2021.573547] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
12 Phull MS, Jadav SS, Gundla R, Mainkar PS. A perspective on medicinal chemistry approaches towards adenomatous polyposis coli and Wnt signal based colorectal cancer inhibitors. Eur J Med Chem 2021;212:113149. [PMID: 33445154 DOI: 10.1016/j.ejmech.2020.113149] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kishore C, Bhadra P. Current advancements and future perspectives of immunotherapy in colorectal cancer research. Eur J Pharmacol 2021;893:173819. [PMID: 33347822 DOI: 10.1016/j.ejphar.2020.173819] [Cited by in Crossref: 34] [Cited by in F6Publishing: 42] [Article Influence: 11.3] [Reference Citation Analysis]
14 Chi L, Xu C, Li S, Wang X, Tang D, Xue F. In situ amplified QCM immunoassay for carcinoembryonic antigen with colorectal cancer using horseradish peroxidase nanospheres and enzymatic biocatalytic precipitation. Analyst 2020;145:6111-8. [DOI: 10.1039/d0an01399d] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]